Clinical Trials Directory

Trials / Completed

CompletedNCT06332365

Evaluating Treatment Efficacy in Oral Lichen Planus: The Role of Salivary Biomarkers

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Pia Lopez Jornet · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Lichen planus, a chronic autoimmune mucocutaneous disorder, affects 0.5% to 2.2% of diverse populations. The treatment for oral lichen planus (OLP) includes a range of options, both topical and systemic therapies. Recent research has highlighted the potential of hyaluronic acid as a drug alternative, potentially offering effective management for OLP and alleviating the discomfort of this chronic condition. The objective was to assess the impact of topical hyaluronic acid on salivary oxidative stress markers in individuals suffering from oral lichen planus

Detailed description

Interventional (Clinical Trial) Actual Enrollment : 60 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Care Provider, Outcomes Assessor) Masking Description: The clinical outcomes were assessed by an investigator masked about the treatment modality that has been used Primary Purpose: Treatment Pain , quality of life the study on oral lichen planus, three treatment groups were established: Group I: Received a combination of 0.1% hyaluronic acid and 0.2% triamcinolone acetonide. Group II: Was treated solely with 0.2% triamcinolone acetonide. Group III: Received only 0.1% hyaluronic acid. These groups were designed to evaluate and compare the efficacy of different treatments in patients with oral lichen planus.

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCTAcetonide triamcinolone 0.2% +hyaluronicacid 1%topical application cream form twice a day for 4 weeks
DRUGCorticoid Acetonide triamcinolone 0.2%topical application cream form twice a day for 4 weeks
DRUGHyaluronic acid 1%topical application cream form twice a day for 4 weeks

Timeline

Start date
2022-01-03
Primary completion
2023-12-15
Completion
2024-02-19
First posted
2024-03-27
Last updated
2024-03-27

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT06332365. Inclusion in this directory is not an endorsement.